XML 20 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]    
Net Revenue $ 45,842,845 $ 24,143,919
Cost of goods sold 6,360,851 2,311,221
Gross profit 39,481,994 21,832,698
Operating expenses    
Selling, general and administrative expenses 45,976,328 28,053,176
Research and development 3,367,032 558,704
Depreciation and amortization 2,371,068 596,975
Total operating expenses 51,714,428 29,208,855
Operating loss (12,232,434) (7,376,157)
Other expense    
Interest and accretion expense (284,746) (711)
Share of losses from equity method investment (379,633) (616,927)
Loss on disposal of investment (1,040,311)
Total other expense (1,704,690) (617,638)
Loss before income taxes (13,937,124) (7,993,795)
Income tax benefit 5,844,796
Net loss (8,092,328) (7,993,795)
Less: Net loss attributable to noncontrolling interest (154,831) (71,881)
Net loss attributable to Sanara MedTech shareholders $ (7,937,497) $ (7,921,914)
Net loss per share of common stock, basic and diluted $ (1.00) $ (1.08)
Weighted average number of common shares outstanding, basic and diluted 7,906,794 7,341,580